Michael Larbig

Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial

Kenneth R. Chapman, John R. Hurst, Stefan Frent et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 262 citations

Medicine, Internal Medicine, Pharmacotherapy +15

One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings

Roland Buhl, Liam G. Heaney, Emil Loefroth et al. · Respiratory Medicine · 2019 · 43 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

The Toll-Like Receptor-2/6 Agonist Macrophage-Activating Lipopeptide-2 Cooperates with IFN-γ to Reverse the Th2 Skew in an In Vitro Allergy Model

Henning Weigt, Peter F. Mühlradt, Michael Larbig et al. · The Journal of Immunology · 2004 · 34 citations · Full text

Life Sciences, Immunology, Allergy +16

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

Antonio Anzueto, Κonstantinos Κostikas, Karen Mezzi et al. · Respiratory Research · 2018 · 33 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers

Veit J. Erpenbeck, Eva Vets, Lien Gheyle et al. · Clinical Pharmacology in Drug Development · 2015 · 24 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +10